Medication optimisation:methodological aspects and new strategies by Mestres Gonzalvo, Carlota
  
 
Medication optimisation
Citation for published version (APA):
Mestres Gonzalvo, C. (2018). Medication optimisation: methodological aspects and new strategies.
Maastricht: Maastricht University. https://doi.org/10.26481/dis.20180412cm
Document status and date:
Published: 01/01/2018
DOI:
10.26481/dis.20180412cm
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
 111 
Valorisation 
   
Valorisation 
 
113 
Polypharmacy is defined as the simultaneous use of more than a certain number of 
drugs, regardless of their appropriateness [1]. Polypharmacy increases as people 
get older and it is estimated that 20% of patients 65 of older is polymedicated [2]. 
Previous studies have shown that polypharmacy increases the risk of drug related 
problems (DRPs) and can lead to hospitalisation [3]. 
Medication optimisation aims at improving health outcomes by optimising the use 
of medication, taking into account the benefits and safety aspects of the used 
drugs; It consists of medication surveillance and medication reviews. Medication 
surveillance is daily (digitally) performed by physicians and/or pharmacists to as-
sure a beneficial and safe use of drugs and combinations of multiple drugs. It alerts 
for drug-drug interactions, drug-disease interactions (contraindications) and incor-
rect dosages. Medication reviews are structured evaluations of a patient’s medi-
cines, patient’s characteristics, and laboratory values performed periodically (man-
ually) aiming at optimal pharmacotherapy. Medication optimisation, the combina-
tion of medication surveillance and medication reviews, is thus aimed at detecting 
DRPs so that interventions can be recommended to prevent unplanned hospital 
admissions [1].  
The fact that medication reviews are performed, at its best, periodically, emphasiz-
es that this traditional way might be out of date, as it is a snapshot of a patient’s 
medication list, characteristics and laboratory results [4, 5].  
A transition towards a more up to date method is essential to guarantee a high-
quality medication optimization process, hopefully showing in clinically relevant 
outcomes. In this way, a computerised decision support system (CCDSS) seems a 
plausible answer. These systems were created in the 70’s to support the clinician 
on making diagnosis and treatment decisions. CCDSS are typically designed to 
integrate a medical knowledge base, patient data and an inference engine to gen-
erate case specific advice [6].  
This thesis puts in perspective the methodological aspects of the medication opti-
mization process and discusses new strategies in the form of CCDSS.  
We have shown that even when having all the available information which 
could lead to a high-quality medication review, its quality leaves much to be 
desired 
Different healthcare professionals (community pharmacists, hospital pharmacists, 
nursing home physicians, general practitioners and geriatricians) ranked the im-
portance of different covariates in order to perform a high-quality medication re-
view. From this survey, we could establish that drug’s indication, use of patients' 
medical history, use of guidelines, reviewer’s professional field, and use of laborato-
ry values are the top 5 covariates that would lead to a high-quality medication 
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review. Subsequently, these covariates were used to perform medication reviews 
and we demonstrated the large variability on their quality.  
The Dutch healthcare inspectorate (IGZ) demands a medication review to be per-
formed twice a year and yearly for all nursing homes residents and elderly home 
residents, respectively. Taking into account the time required to perform a medica-
tion review, the disappointing quality of the medication reviews performed and the 
lack of proven efficacy, it is surprising that the healthcare inspectorate requires the 
medication reviews to be performed. A multidisciplinary working group is adapting 
the guidelines which patient should be reviewed in order to make it more feasible 
for general practitioners and pharmacists. They suggest an increase of both the age 
and the number of drugs used, thereby discarding the view that early detection of 
DRP’s leads to prevention and minimising damage. 
Given these facts and taking into account the time needed to perform a medication 
review, a more efficient way is needed to fulfil the expectations. Furthermore, a 
longitudinal or continuous medication therapy management would be a better 
approach than a cross-sectional approach to assure optimal pharmacotherapy.  
This thesis shows which aspects should be considered to optimise the efficien-
cy when performing medication review supported by a CCDSS 
Using a CCDSS to perform medication reviews might lead to a significant time re-
duction increasing the process efficiency.  
The content of a CCDSS is known as clinical rules which are the algorithms generat-
ing patient-specific assessments or treatment recommendations. Clinical rules as-
sign sign- or symptom-based probability scores to risk stratify patients for specific 
prognoses and/or diagnostic assessments.  
Optimising the clinical rules is the first step towards a high-quality medication op-
timisation. In this way alerts are generated only when action is required. For exam-
ple, an alert is generated according to renal function value and drug dose. In the 
basic medication surveillance, an alert is generated for each drug whose dose 
should be adjusted to the renal function without taking into account either the 
renal function or the dose. In order to prevent alert fatigue on one hand, but also 
missing important alerts on the other hand, we aim at a clinical efficacy of 80%. We 
realise however that this 80% is not evidence based. This might be a topic for fu-
ture research. 
Simple clinical rules can be used to identify patients eligible for treatment op-
timisation, making the screening process more efficient and objective 
Clinical rules can also be used to select a group of patients eligible for a specific 
treatment based on beforehand established parameters. Within this project a clini-
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cal rule to promote the discontinuation of chronically used BZ/Z for insomnia in the 
nursing home setting was developed.  
Even though the discontinuation rate was rather low, we have shown that a simple 
clinical rule can screen more than 800 patients and generate a list within minutes of 
the patients which according to guidelines are qualify for discontinuation. In addi-
tion, when using a clinical rule no patient is missed and the same criteria is objec-
tively applied to screen all patients. This approach makes it possible to run this 
clinical rule more frequently, e.g. on a weekly basis. 
We have validated an automated delirium prediction model which by means of 
a clinical rule can predict patients at risk of delirium within 5 days after analysis 
Delirium is an under-diagnosed, severe, and costly disorder, and 30-40% of cases 
can be prevented [7]. A fully automated model to predict delirium (DEMO) in older 
people was developed and has been validated in this thesis.  
Patients admitted in the hospital are automatically screened within 24 hours from 
admission. DEMO predicts patients at risk of developing a delirium within 5 days 
after analysis. The high sensitivity and specificity found in the validation study 
make the model satisfactory to be applied in clinical practice to facilitate earlier 
recognition and diagnosis of delirium. Nevertheless, important factors that could 
predict delirium (previous delirium, cognitive impairment, severity of disease, visual 
impairment, etc.) are not included in this model as these data are not yet electroni-
cally available.  
Using a CCDSS will drastically reduce the time to perform a medication review 
and hopefully demonstrate a positive effect on clinically relevant outcomes 
compared to traditional medication review 
Clinical trials are not widely applied for medical informatics. In addition, there is a 
lack of focus on the impact of a CCDSS on clinical outcomes. We present a RCT 
study design focused on both hard endpoints (i.e., patient relevant outcomes) and 
surrogate out-comes, aiming at demonstrating a positive effect on clinically rele-
vant outcomes when using a CCDSS vs traditional medication optimisation in the 
nursing home setting.  
The overall goal from the medication optimisation viewpoint is to improve patient 
care; thus, the use of a CCDSS should be evaluated on clinical outcomes. This 
should be the subject of future re-search, of which the first steps already have been 
undertaken. 
In addition, using a CCDSS to support the medication review process decreases the 
time needed to evaluate the appropriateness of medication so that healthcare profes-
sionals can focus on what is important and perform a high-quality medication review. 
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